Market Overview

Merck, GE Healthcare Announce Collaboration on Use of Imaging Biomarkers for Investigational BACE Inhibitor Program

Share:
Related MRK
Fast Money Halftime Report Final Trade From January 27
White House Budget To Support Biotech Rally
Foreign Currency Headwinds Take The Spotlight In Drug Maker Earnings (Seeking Alpha)
Related GE
Paul La Monica Suggests General Electric 'Isn't The Bellwether It Once Was'
UPDATE: Credit Suisse Lowers Price Target On General Electric Following Q4 Earnings
Sorry, But 3M Has Become Too Expensive, General Electric Is The Better Deal (Seeking Alpha)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration, license and supply agreement for use of [^18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

Accumulation of beta amyloid in the brain is a pathological characteristic related to Alzheimer's disease. Currently, AD is diagnosed by clinical examination (i.e., medical history, physical, neurological, psychiatric and neuropsychological exams, laboratory tests and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be confirmed through histopathological identification of characteristic features, including beta amyloid plaques, in post-mortem brain samples.

Posted-In: News

 

Related Articles (GE + MRK)

Around the Web, We're Loving...

Get Benzinga's Newsletters